Semaphorin 3A (Sema3A) as an immune modulator could participate in the pathogenesis of autoimmune diseases. In the current study, we aimed to investigate Sema3A expression in peripheral blood mononuclear cells (PBMCs) and its serum level in relapsing-remitting multiple sclerosis (RRMS) patients. Fifteen newly determined and untreated RRMS patients were chosen and assessed in relapsing and remitting phases in compare with fifteen healthy individuals. In consistent with previous findings in other autoimmune diseases, our results revealed that serum level of Sema3A and its expression in PBMCs of RRMS patients were significantly lower than in normal subjects. We also evaluated this down regulation predictive value with ROC analysis. According to our data, we suggest that Sema3A could be involved in pathogenesis of MS and might be a potential diagnostic biomarker for the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gene.2017.02.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between T-helper 1 Inflammatory Biomarkers and Hematological Index Responses in Patients With Multiple Sclerosis.
Cureus
December 2024
Basic Sciences, Hawler Medical University, Erbil, IRQ.
Background Multiple sclerosis is a chronic, progressive, disabling disease associated with a high rate of infection, evidence of chronic inflammation, and a high mortality rate. Abnormalities of serum cytokines and changes in the activity of inflammatory cells were associated with relapsing-remitting multiple sclerosis (MS-RR). This study aims to introduce new inflammatory ratios derived from hematological and lipid indices as discriminators of T-helper (Th)-1/Th-2 activity in RR-MS.
View Article and Find Full Text PDFEffects of Acupuncture on Cognitive Functions in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.
Chin J Integr Med
January 2025
Department of Acupuncture and Moxibustion, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Objective: To explore the effects of acupuncture in comparison with sham acupuncture on cognitive functions in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: In this randomized controlled trial, 31 RRMS patients in the acupuncture group were treated with traditional Chinese acupuncture based on the treatment principle of calming the mind, reinforcing qi and blood, and 31 patients in the control group were treated with sham acupuncture (shallow needling at non-acupuncture points) twice a week for 12 weeks. The primary outcome was the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) score, which was evaluated by a psychologist at baseline and after 12 weeks of treatment.
[Care and Treatment Guarantee Plan for Patients with Multiple Sclerosis: Impact on Beneficiaries of the Chilean Public System 2008-2018].
Rev Med Chil
July 2024
Servicio de Neurología, Complejo Asistencial Barros Luco Trudeau, Santiago, Chile.
Unlabelled: Multiple sclerosis (MS) is a pathology that mainly affects the young population, causing irreversible disability without treatment. The national multiple sclerosis program improves access to diagnosis, treatment, and prognostic of patients with relapsing-remitting multiple sclerosis (RRMS).
Aim: Describe the biggest cohort of patients with RRMS in the Chilean public health system, analyze the impact of the national program in the clinical evolution and the diagnostic opportunity (time in years between the first outbreak and entry into the program) before and after 2010, date of incorporation of the pathology to the explicit health guarantees program (GES) of the Ministry of Health (MINSAL).
Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
Mult Scler
January 2025
Departamento de Neurología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background: Real-world studies are needed to expand our knowledge concerning populations underrepresented in clinical trials.
Objective: This study aimed to evaluate the safety and effectiveness of ocrelizumab in Hispanic/Latino people with multiple sclerosis (pwMS).
Methods: Prospective longitudinal observational study including pwMS who received at least one dose of ocrelizumab between June 2018 and October 2023.
Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review.
Ann Surg Oncol
January 2025
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Background: Bilateral risk-reducing mastectomies (RRMs) have been proven to decrease the risk of breast cancer in patients at high risk owing to family history or having pathogenic genetic mutations. However, few resources with consolidated data have detailed the patient experience following surgery. This systematic review features patient-reported outcomes for patients with no breast cancer history in the year after their bilateral RRM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!